Ferrer Earns Compliance Leader Verification™ for Exemplary Ethical and Responsible Corporate Practices Ferrer, a globally recognized pharmaceutical company, has been awarded the prestigious Compliance Leader Verification™ by Ethisphere, an organization…
Virpax Pharmaceuticals Announces Public Offering Pricing to Fuel Drug Development and Innovation Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX), a forward-thinking preclinical-stage pharmaceutical company specializing in groundbreaking drug delivery systems for pain…
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, has unveiled groundbreaking new data from the Phase III CALGB (Alliance) / SWOG 80702 study. These findings…
Bristol Myers Squibb Presents Results from CheckMate-8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy in MSI-H/dMMR Metastatic Colorectal Cancer Bristol Myers Squibb (NYSE: BMY) has announced…
Exelixis Reports Positive STELLAR-001 Results for Zanzalintinib in Metastatic CRC at ASCO GI 2025 Exelixis Announces Promising Results from Phase 1b/2 STELLAR-001 Trial for Zanzalintinib in Metastatic Colorectal Cancer at…
Cancer Trial Data for FOG-001 to be Presented by Parabilis at ASCO GI Cancers Symposium Parabilis Medicines, formerly known as Fog Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing transformative…
Verastem Oncology Unveils Bold 2025 Priorities for RAS/MAPK Pathway Cancer Pipeline Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to advancing new treatments for RAS/MAPK pathway-driven cancers, has outlined its…
Vaccines Development: Vaxxas and CEPI Advance $4.8M Program for Needle-Free mRNA Vaxxas, a clinical-stage biotechnology company focused on commercializing its innovative high-density microarray patch (HD-MAP) vaccination platform, today announced that…
Pancreatic Cancer Subtypes Unveiled by BPGbio at ASCO GI 2025 for Tailored Treatment BPGbio, Inc., a clinical-stage biopharma company specializing in mitochondrial biology and protein homeostasis, today revealed new findings…
DNA Nanobots Appoints Dr. John C. Byrd to Scientific Advisory Board DNA Nanobots, a leader in biotechnology specializing in DNA nanoparticles for targeted therapeutics, has announced the addition of Dr.…
Glox Therapeutics Wins £3M Cystic Fibrosis Funding Glox Therapeutics, a leader in developing precision antibiotic therapies using naturally occurring bacteriocins, has announced it has been awarded a portion of the…
Agreement Between InnoCare, KeyMed, and Prolium for CD20xCD3 Bispecific Antibody License InnoCare Pharma (HKEX: 09969; SSE: 688428) and KeyMed Biosciences (HKEX: 02162) have announced the signing of an exclusive license…